List of Excipients in Branded Drug TOLAK

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
HILL DERMACEUTICALS INC	TOLAK	fluorouracil	28105-421	ANHYDROUS CITRIC ACID
HILL DERMACEUTICALS INC	TOLAK	fluorouracil	28105-421	BUTYLATED HYDROXYTOLUENE
HILL DERMACEUTICALS INC	TOLAK	fluorouracil	28105-421	CETYL ALCOHOL
HILL DERMACEUTICALS INC	TOLAK	fluorouracil	28105-421	GLYCERIN
HILL DERMACEUTICALS INC	TOLAK	fluorouracil	28105-421	GLYCERYL MONOSTEARATE

TOLAK Excipient Strategy and Commercial Opportunities

Last updated: September 19, 2026

TOLAK is a fluorouracil 4% topical cream for actinic keratosis of the face and anterior scalp. Its commercial position depends less on active-ingredient exclusivity than on formulation tolerability, product differentiation, topical bioequivalence, physician familiarity, and payer access. The strongest opportunities are improved vehicle design, preservative and packaging optimization, private-label or authorized-generic strategies, and differentiated delivery formats.

What is TOLAK and how is it used?

TOLAK contains fluorouracil 4% in a topical cream developed for once- or twice-daily treatment over a defined course, depending on clinical response and prescribing instructions. The FDA-approved indication is the topical treatment of actinic keratosis on the face and anterior scalp in adults. The product is marketed by Hill Dermaceuticals, LLC.[1]

Attribute	TOLAK profile
Active ingredient	Fluorouracil
Strength	4%
Dosage form	Topical cream
FDA indication	Actinic keratosis of the face and anterior scalp
NDA	207071
Initial FDA approval	2015
Product type	Small-molecule topical drug
Primary competitors	Generic fluorouracil 5%, Efudex, Carac, fluorouracil 2% and other topical products
Biosimilar exposure	None
Main commercial risk	Generic topical substitution and payer pressure

TOLAK occupies a middle position between older fluorouracil 5% creams and lower-strength formulations such as fluorouracil 0.5%. The 4% concentration provides a product-specific formulation and dosing proposition, but fluorouracil itself is an established active ingredient with extensive generic competition.

What excipients are used in TOLAK?

The TOLAK label identifies a conventional oil-in-water cream system. Listed inactive ingredients include benzyl alcohol, cetearyl alcohol, cetyl alcohol, dimethicone, glyceryl stearate, methylparaben, polysorbate 60, propylene glycol, purified water, sodium hydroxide, and stearic acid.[1]

Excipient	Functional role	Commercial relevance
Benzyl alcohol	Preservative and solvent	Can affect tolerability and preservative sensitivity
Cetearyl alcohol	Emollient, thickener, co-emulsifier	Supports cream body and skin feel
Cetyl alcohol	Emollient and consistency agent	Affects spreadability and residue
Dimethicone	Skin protectant and occlusive agent	May improve barrier feel and reduce dryness
Glyceryl stearate	Emulsifier and emollient	Supports physical stability
Methylparaben	Preservative	Provides microbial protection but may limit “preservative-free” positioning
Polysorbate 60	Surfactant and emulsifier	Supports oil-water dispersion
Propylene glycol	Humectant and solvent	Can improve hydration and drug partitioning but may sting
Sodium hydroxide	pH adjustment	Controls formulation pH and stability
Stearic acid	Emollient and structuring agent	Contributes to viscosity and cream texture
Purified water	Continuous phase	Primary vehicle component

The formulation is commercially important because topical fluorouracil causes predictable local reactions, including erythema, inflammation, irritation, pain, pruritus, and erosion. Excipients cannot eliminate the pharmacologic reaction, but they can influence spreadability, hydration, sting, residue, skin barrier effects, and patient willingness to complete treatment.

How strong is the TOLAK formulation strategy?

TOLAK’s excipient strategy is functional rather than radically novel. It uses familiar dermatological cream ingredients with established manufacturing supply chains. This lowers production complexity and regulatory risk, but it also limits formulation-based differentiation unless the sponsor can demonstrate superior tolerability, adherence, stability, or patient preference.

The main technical strengths are:

1. A conventional cream platform with broad manufacturing availability.
2. Multiple emollient and structuring agents that support a stable semisolid product.
3. Dimethicone and fatty alcohols that may improve skin feel during an inflammatory treatment course.
4. Propylene glycol, which can support hydration and active-ingredient delivery.
5. A formulation architecture that is suitable for tube packaging and routine dermatology dispensing.

The main vulnerabilities are:

1. Benzyl alcohol and propylene glycol can contribute to stinging or irritation in sensitive skin.
2. Methylparaben creates a limitation for consumers seeking preservative-free products.
3. Conventional emulsions can experience changes in viscosity, phase behavior, or drug distribution during accelerated storage.
4. The excipient set is familiar enough that a competitor may develop a cosmetically improved vehicle without requiring an entirely new delivery platform.
5. Generic applicants may be able to use alternative inactive ingredients if they demonstrate pharmaceutical equivalence and bioequivalence under the applicable FDA pathway.

What formulation opportunities exist for TOLAK or competing fluorouracil products?

The largest opportunity is a better-tolerated vehicle that maintains fluorouracil delivery while reducing sensory objections. Relevant development areas include the following.

Low-sting and barrier-supportive creams

A vehicle with reduced levels of potentially irritating solvents, optimized pH, and stronger barrier-supportive properties could improve patient acceptance. Candidate excipient classes include ceramide systems, fatty-acid blends, cholesterol-containing emulsions, colloidal oatmeal, and alternative humectants.

The commercial challenge is that a more complex barrier formulation can increase manufacturing cost, create supply-chain dependencies, and complicate topical bioequivalence.

Preservative-reduced or preservative-free packaging

Multidose tubes generally require microbiological protection. Airless pumps, unit-dose sachets, or other low-contamination packaging could support a preservative-reduced strategy. This creates a potential premium product, especially for patients with sensitive skin or known preservative intolerance.

Packaging changes may affect extractables and leachables, fill-weight controls, dose uniformity, and stability. A preservative-free claim would require strong microbiological and container-closure data.

Improved spreadability

A cream that spreads rapidly with less rubbing could reduce discomfort on inflamed skin. This is relevant because actinic keratosis treatment often covers broad areas rather than isolated lesions. Possible approaches include lower-yield-stress emulsions, optimized fatty alcohol ratios, lighter silicone systems, and gel-cream hybrids.

A thinner product may improve usability but could reduce residence time, increase migration toward the eyes, or alter drug release.

Foam, gel, lotion, and spray formats

Alternative dosage forms can target patients who dislike a conventional cream. The principal opportunities are:

• Low-residue lotion for large treatment areas.
• Gel-cream for rapid absorption.
• Foam for scalp or hair-bearing regions.
• Spray or metered pump for contact-minimizing application.
• Film-forming systems for controlled residence time.

Each format creates regulatory and technical challenges. The dosage form must preserve fluorouracil stability, deliver a consistent dose, and meet topical bioequivalence expectations. A spray also introduces device performance, plume, priming, and dose-uniformity requirements.

What patent protection covers TOLAK?

TOLAK’s principal protection is unlikely to rest on the novelty of fluorouracil itself. Fluorouracil is an old active ingredient, and the key intellectual-property value would be associated with the specific composition, manufacturing process, delivery system, or clinical use.

Potential protection categories include:

Protection category	Relevance to TOLAK
Active ingredient patent	Weak or unavailable because fluorouracil is long established
Composition patent	Could cover defined excipient ranges, ratios, pH, viscosity, or stability
Method-of-use patent	Could cover treatment duration, patient subgroup, dosing schedule, or anatomical site
Manufacturing patent	Could cover mixing order, temperature profile, homogenization, or drug incorporation
Packaging patent	Could cover an airless pump, dose-metering system, or preservative-reduction design
Trade secret	May protect process parameters, scale-up methods, and quality controls
Trademark protection	Protects the TOLAK brand but not the underlying fluorouracil formulation

The FDA label identifies the product and its approved use but does not establish the full private patent estate. Orange Book patent listings, continuation applications, and non-U.S. rights must be evaluated separately in a current patent search. The commercially relevant question is whether any composition or method-of-use patent is listed against the NDA and whether an ANDA applicant must address that patent through a Paragraph IV certification.

What is the Orange Book status and generic entry risk for TOLAK?

TOLAK is an NDA product subject to the FDA’s drug-listing and Orange Book framework. Fluorouracil 4% is vulnerable to generic competition because the active ingredient is well established and the product is a topical small-molecule formulation rather than a biologic.[2]

The key generic-entry pathways are:

1. An ANDA for a fluorouracil 4% cream that demonstrates pharmaceutical equivalence and bioequivalence.
2. A 505(b)(2) application for a materially different formulation, dosage form, strength, or delivery system.
3. A competing fluorouracil product at another strength that creates therapeutic substitution pressure.
4. Authorized-generic or private-label commercialization using the same or substantially similar product.

For topical semisolid products, FDA review can involve comparative physicochemical characterization, formulation sameness or similarity, in vitro release testing, and, depending on the product and guidance, clinical or pharmacodynamic studies. FDA’s product-specific guidance should control development planning.[3]

When does TOLAK lose exclusivity?

TOLAK’s regulatory exclusivity is limited relative to a new molecular entity because fluorouracil is an established active ingredient. Any three-year exclusivity would have been tied to the approval of new clinical investigations rather than new chemical entity status. That period would not provide the long-duration protection associated with a new active ingredient.

Patent expiry cannot be determined from the product label alone. The relevant commercial dates depend on any issued composition, method-of-use, manufacturing, or formulation patents that are listed or otherwise enforceable. A generic launch analysis should therefore distinguish:

• FDA regulatory exclusivity;
• Orange Book-listed patents;
• unlisted formulation or process patents;
• trade-secret protection;
• trademark and brand-prescription effects.

The absence of strong active-ingredient protection means that TOLAK’s practical exclusivity is primarily formulation- and brand-based.

Which companies are challenging TOLAK?

The competitive set includes manufacturers of generic fluorouracil creams and branded or legacy fluorouracil products. Major market pressure comes from generic fluorouracil 5% products, which are commonly available and familiar to dermatologists.

Direct competition can arise even without a 4% generic. Physicians may prescribe:

• Fluorouracil 5% cream, including generic products;
• Fluorouracil 0.5% cream;
• Fluorouracil 2% formulations where available;
• Imiquimod;
• Diclofenac sodium gel;
• Tirbanibulin ointment;
• Photodynamic therapy;
• Cryotherapy for discrete lesions.

The most important competitive distinction is treatment experience. A 4% product may be selected when the prescriber values its specific formulation or perceived tolerability, but a lower-cost 5% generic can capture patients through formulary preference and pharmacy substitution.

Does TOLAK face biosimilar risk?

No. TOLAK contains fluorouracil, a synthetic small molecule. Biosimilar approval under the Public Health Service Act does not apply. The relevant threat is generic or alternative topical competition under the Federal Food, Drug, and Cosmetic Act.

This distinction matters commercially. A biosimilar competitor would normally require biologic comparability and could be affected by complex biologic patent litigation. TOLAK instead faces conventional formulation, ANDA, 505(b)(2), pricing, and substitution risks.

What commercial opportunities exist for TOLAK?

Premium dermatology positioning

The brand can support a premium strategy based on product consistency, tolerability messaging, patient support, and physician familiarity. This strategy requires evidence beyond the active ingredient, such as patient preference, adherence, reduced discontinuation, or improved treatment experience.

Private-label and licensing deals

A formulation owner could license:

• A fluorouracil 4% cream to a dermatology-focused commercial partner.
• A preservative-reduced product to a specialty pharmacy platform.
• A foam, lotion, or pump format to a consumer-health company.
• Manufacturing rights by territory.
• An authorized generic or co-branded generic version.

The most attractive licensees would have dermatology sales channels, payer contracting capability, and access to specialty pharmacies.

Geographic expansion

The product concept can be adapted for markets where actinic keratosis prevalence is high, including North America, Australia, and parts of Europe. Regulatory requirements differ by jurisdiction, and approval may depend on local clinical data, topical bioequivalence standards, and classification of the product as a medicinal cream.

Manufacturing and supply-chain opportunity

The listed excipients are broadly available, which supports multi-source procurement. Commercial resilience can improve through:

• Dual sourcing of preservatives and emulsifiers;
• Validated alternate grades of fatty alcohols;
• Regional tube and carton suppliers;
• In-process controls for viscosity and particle or droplet distribution;
• Tight control of pH and fluorouracil assay;
• Defined hold-time studies for bulk cream.

A major manufacturing barrier would arise if the product depends on a narrow excipient grade, proprietary mixing sequence, or difficult scale-up process. Those barriers can create trade-secret value even when patent protection is limited.

How does TOLAK compare with generic fluorouracil 5%?

Factor	TOLAK	Generic fluorouracil 5%
Strength	4%	Commonly 5%
Brand status	Branded NDA product	ANDA products
Formulation differentiation	Specific branded cream vehicle	Varies by manufacturer
Price position	Usually higher	Usually lower
Generic substitution	Direct risk	Established market
Biosimilar risk	None	None
Main advantage	Branded formulation and prescribing familiarity	Cost and availability
Main vulnerability	Payer and substitution pressure	Variable patient experience by manufacturer

TOLAK’s value proposition must therefore be formulated around the total treatment experience, not concentration alone. A 4% strength is commercially meaningful only if the vehicle, tolerability, adherence, or payer positioning creates a measurable advantage.

What revenue exposure does TOLAK create?

Standalone TOLAK revenue is not publicly reported in the cited FDA materials. The exposure profile can still be assessed:

• High exposure to generic substitution if a 4% ANDA enters the market.
• Moderate exposure to 5% generic competition even without a direct 4% generic.
• Low exposure to biosimilar competition.
• Moderate exposure to payer formulary exclusions and step therapy.
• Potential upside from new delivery formats and international licensing.
• Potential margin pressure from preservative, tube, and emulsion-component costs.

The best commercial opportunities are products that reduce application discomfort, improve adherence, or simplify application over large treatment areas. A reformulation that changes only texture without clinical or patient-reported evidence would face limited pricing power.

What litigation and settlement risks apply?

Potential litigation would most likely involve:

• Paragraph IV challenges to listed composition or method-of-use patents;
• ANDA litigation under the Hatch-Waxman framework;
• Trademark disputes involving TOLAK branding;
• Trade-secret claims related to manufacturing;
• Product-liability claims involving severe local reactions or misuse.

No biosimilar litigation pathway applies. Settlement agreements, if any, would require review of court dockets, FDA patent certifications, and applicable antitrust disclosures. A commercial launch assessment should separate patent litigation from ordinary generic competition, because a formulation may remain commercially vulnerable even when no patent lawsuit is filed.

Key Takeaways

• TOLAK is a fluorouracil 4% cream approved for actinic keratosis of the face and anterior scalp.
• Its excipient system is a conventional emulsion containing fatty alcohols, glyceryl stearate, polysorbate 60, propylene glycol, dimethicone, benzyl alcohol, and methylparaben.
• The strongest formulation opportunities are reduced-sting vehicles, preservative-reduced packaging, improved spreadability, and alternative formats such as lotion, foam, gel-cream, or metered delivery.
• TOLAK has no biosimilar risk because fluorouracil is a small molecule.
• Generic risk comes from direct fluorouracil 4% ANDAs, existing fluorouracil 5% products, and 505(b)(2) formulations.
• Patent value, if available, would likely reside in composition, manufacturing, delivery, or method-of-use claims rather than fluorouracil itself.
• Licensing opportunities exist in dermatology-focused commercialization, private-label supply, authorized generics, international expansion, and improved delivery systems.
• The commercial case for a premium product requires evidence of better tolerability, adherence, usability, or patient preference.

FAQs

Can a generic manufacturer copy the TOLAK excipients?

A generic applicant may use the same or different inactive ingredients if it satisfies FDA pharmaceutical-equivalence and bioequivalence requirements. The applicant must also address any applicable listed patents.

Is fluorouracil 4% stronger than fluorouracil 5%?

By concentration, 4% contains less fluorouracil than 5%. Clinical performance cannot be determined from concentration alone because vehicle composition, drug release, application schedule, treatment area, and tolerability also affect outcomes.

Could a preservative-free TOLAK alternative command a premium price?

Potentially, but the product would need microbiological, packaging, stability, and clinical usability data. A preservative-free claim alone may not justify premium pricing without evidence of improved tolerability or adherence.

What is the most defensible new product based on TOLAK?

A differentiated topical delivery system with documented patient-preference or tolerability benefits is more defensible than a simple excipient substitution. Metered-dose, low-sting, barrier-supportive, or large-area application formats offer the clearest development rationale.

Is a fluorouracil foam more commercially attractive than a cream?

A foam may have advantages on the scalp and hair-bearing areas, but it introduces higher formulation, packaging, and device complexity. Its commercial value depends on meaningful improvements in application, residue, adherence, or treatment coverage.

References

1. U.S. Food and Drug Administration. (2015). Tolak (fluorouracil) cream, 4%: Prescribing information.
2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2024). Product-specific guidance for topical dermatological drug products.
4. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database.
5. DailyMed. (2025). Tolak: Fluorouracil cream, 4%. National Library of Medicine.